193 related articles for article (PubMed ID: 17579472)
1. Radiolabeled divalent peptidomimetic vitronectin receptor antagonists as potential tumor radiotherapeutic and imaging agents.
Harris TD; Cheesman E; Harris AR; Sachleben R; Edwards DS; Liu S; Bartis J; Ellars C; Onthank D; Yalamanchili P; Heminway S; Silva P; Robinson S; Lazewatsky J; Rajopadhye M; Barrett J
Bioconjug Chem; 2007; 18(4):1266-79. PubMed ID: 17579472
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy.
Harris TD; Kalogeropoulos S; Nguyen T; Liu S; Bartis J; Ellars C; Edwards S; Onthank D; Silva P; Yalamanchili P; Robinson S; Lazewatsky J; Barrett J; Bozarth J
Cancer Biother Radiopharm; 2003 Aug; 18(4):627-41. PubMed ID: 14503959
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of 111In- and 99mTc-labeled quinolin-4-one peptidomimetics as ligands for the vitronectin receptor: potential tumor imaging agents.
Harris TD; Kalogeropoulos S; Nguyen T; Dwyer G; Edwards DS; Liu S; Bartis J; Ellars C; Onthank D; Yalamanchili P; Heminway S; Robinson S; Lazewatsky J; Barrett J
Bioconjug Chem; 2006; 17(5):1294-313. PubMed ID: 16984141
[TBL] [Abstract][Full Text] [Related]
4. 90Y and 111In complexes of a DOTA-conjugated integrin alpha v beta 3 receptor antagonist: different but biologically equivalent.
Onthank DC; Liu S; Silva PJ; Barrett JA; Harris TD; Robinson SP; Edwards DS
Bioconjug Chem; 2004; 15(2):235-41. PubMed ID: 15025518
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo evaluation of 177Lu- and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers.
Giblin MF; Sieckman GL; Shelton TD; Hoffman TJ; Forte LR; Volkert WA
Nucl Med Biol; 2006 May; 33(4):481-8. PubMed ID: 16720239
[TBL] [Abstract][Full Text] [Related]
6. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
[TBL] [Abstract][Full Text] [Related]
7. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.
de Visser M; Janssen PJ; Srinivasan A; Reubi JC; Waser B; Erion JL; Schmidt MA; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1134-9. PubMed ID: 12768332
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeled high affinity peptidomimetic antagonist selectively targets alpha(v)beta(3) receptor-positive tumor in mice.
Jang BS; Lim E; Hee Park S; Shin IS; Danthi SN; Hwang IS; Le N; Yu S; Xie J; Li KC; Carrasquillo JA; Paik CH
Nucl Med Biol; 2007 May; 34(4):363-70. PubMed ID: 17499725
[TBL] [Abstract][Full Text] [Related]
9. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide.
Dijkgraaf I; Liu S; Kruijtzer JA; Soede AC; Oyen WJ; Liskamp RM; Corstens FH; Boerman OC
Nucl Med Biol; 2007 Jan; 34(1):29-35. PubMed ID: 17210459
[TBL] [Abstract][Full Text] [Related]
10. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo characterization of three 68Ga- and 111In-labeled peptides for cholecystokinin receptor imaging.
Roosenburg S; Laverman P; Joosten L; Eek A; Rutjes FP; van Delft FL; Boerman OC
Mol Imaging; 2012; 11(5):401-7. PubMed ID: 22954184
[TBL] [Abstract][Full Text] [Related]
12. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
[TBL] [Abstract][Full Text] [Related]
13. Use of antibody as carrier of oligomers of peptidomimetic alphavbeta3 antagonist to target tumor-induced neovasculature.
Shin IS; Jang BS; Danthi SN; Xie J; Yu S; Le N; Maeng JS; Hwang IS; Li KC; Carrasquillo JA; Paik CH
Bioconjug Chem; 2007; 18(3):821-8. PubMed ID: 17375899
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors.
Zhang H; Chen J; Waldherr C; Hinni K; Waser B; Reubi JC; Maecke HR
Cancer Res; 2004 Sep; 64(18):6707-15. PubMed ID: 15374988
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
Vallabhajosula S; Kuji I; Hamacher KA; Konishi S; Kostakoglu L; Kothari PA; Milowski MI; Nanus DM; Bander NH; Goldsmith SJ
J Nucl Med; 2005 Apr; 46(4):634-41. PubMed ID: 15809486
[TBL] [Abstract][Full Text] [Related]
16. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
17. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy.
Pan MH; Gao DW; Feng J; He J; Seo Y; Tedesco J; Wolodzko JG; Hasegawa BH; Franc BL
Mol Imaging Biol; 2009; 11(3):159-66. PubMed ID: 19034582
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of potent alphavbeta3-integrin receptor antagonists.
Dijkgraaf I; Kruijtzer JA; Frielink C; Soede AC; Hilbers HW; Oyen WJ; Corstens FH; Liskamp RM; Boerman OC
Nucl Med Biol; 2006 Nov; 33(8):953-61. PubMed ID: 17127167
[TBL] [Abstract][Full Text] [Related]
19. Anaerobic 90Y- and 177Lu-labeling of a DOTA-conjugated nonpeptide vitronectin receptor antagonist.
Liu S; Harris TD; Ellars CE; Edwards DS
Bioconjug Chem; 2003; 14(5):1030-7. PubMed ID: 13129408
[TBL] [Abstract][Full Text] [Related]
20. 177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation.
Das T; Chakraborty S; Unni PR; Banerjee S; Samuel G; Sarma HD; Venkatesh M; Pillai MR
Appl Radiat Isot; 2002 Aug; 57(2):177-84. PubMed ID: 12150276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
